Ann: Termination of Supply Agreement, page-97

First 97 Last

Share
Profile

Follow
bavarian1975

3,142 Posts.

1599

02/05/22

13:41

Post #: 61147207
Share

Originally posted by Brightshiny1: ↑

https://www.msd-australia.com.au/news/cancer-therapies-receive-recommendations-from-the-pharmaceutical-benefits-advisory-committee/27/4/2021

KEYTRUDA SELECTED SAFETY INFORMATION2 Precautions: Immune-mediated adverse reactions (ImARs), incl. severe and fatal cases, have occurred in patients receiving KEYTRUDA. These have included, but not limited to: pneumonitis, colitis, hepatitis, hepatoxicity (in combination with axitinib), nephritis, endocrinopathies (adrenal insufficiency, hypophysitis, type 1 diabetes mellitus, hyperthyroidism, hypothyroidism, thyroiditis), severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis and bullous pemphigoid), uveitis, myositis, Guillain-Barre syndrome, pancreatitis, encephalitis, sarcoidosis, myasthenic syndrome/myasthenia gravis (incl. exacerbation), myelitis, vasculitis, myocarditis, pericarditis and pericardial effusion, peripheral neuropathy, sclerosing cholangitis, solid organ transplant rejection, severe infusion reactions (hypersensitivity, anaphylaxis) and complications of allogeneic HSCT. ImARs have occurred after discontinuation of treatment with KEYTRUDA. ImARs can affect more than one body system simultaneously. Thyroid and liver function tests should be performed at baseline, periodically during treatment and as indicated based on clinical evaluation. Withhold or discontinue KEYTRUDA to manage adverse reactions as described in the Product Information. Adverse events: In patients with endometrial carcinoma treated with KEYTRUDA/LENVIMA, the following adverse events occurred at a rate >20% and at a rate higher than doxorubicin or paclitaxel were: hypothyroidism (67% vs 0.9%), hypertension (67% vs 6%), haemorrhagic events (25% vs 15%), fatigue (58% vs 54%), diarrhoea (55% vs 20%), nausea (49% vs 47%), vomiting (37% vs 21%), stomatitis (35% vs 26%), abdominal pain (34% vs 21%), constipation (27% vs 25%), musculoskeletal disorders (53% vs 27%), decreased appetite (44% vs 21%), weight loss (34% vs 6%), proteinuria (29% vs 3.4%), urinary tract infection (31% vs 13%) , headache (26% vs 9%), dysphonia (22% vs 0.6%), palmar-plantar erythrodysesthesia (23% vs 0.9%) and rash (20% vs 4.9%). Fatal adverse events have occurred. In patients with head and neck cancer, KEYTRUDA was discontinued for adverse reactions in 12% of patients in the KEYTRUDA single agent arm. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were sepsis (1.7%) and pneumonia (1.3%). Adverse reactions leading to the interruption of KEYTRUDA occurred in 31% of patients; the most common adverse reactions leading to interruption of KEYTRUDA (≥2%) were pneumonia (2.3%), pneumonitis (2.3%), and hyponatremia (2%). KEYTRUDA was discontinued for adverse reactions in 16% of patients in the combination arm. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). Adverse reactions leading to the interruption of KEYTRUDA occurred in 45% of patients; the most common adverse reactions leading to interruption of KEYTRUDA (≥2%) were neutropenia (14%), thrombocytopenia (10%), anaemia (6%), pneumonia (4.7%), and febrile neutropenia (2.9%). Contraindications: None.Refer to the Consumer Medical Information leaflet, available online or your doctor or pharmacist for further information about KEYTRUDA.I'm guessing that this has something to do with it, an article from MSD website last week, Imugene probably has cold feet.

Expand

But if they had cold feet, why would they continue with the trial?I m reading it that they continue with the trial, but now will supply Merck product for it.

IMU Price at posting: 20.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

PME

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

JBY

James Bay latest lithium player to pivot to other metals amidst lithium slump

ASX Market Update: Index pulls back from record highs | October 16, 2024

There are more pages in this discussion • 352 more messages in this thread...

First 97 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.9¢		Change 0.000(0.00%)		Mkt cap ! $364.4M

Open	High	Low	Value	Volume
4.9¢	5.0¢	4.9¢	$900.1K	18.37M

Buyers (Bids)

No.	Vol.	Price($)
102	15456501	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	1713619	8

View Market Depth

No.	Vol.	Price($)
102	15456501	0.048
63	7620458	0.047
37	4709023	0.046
53	5098365	0.045
10	892291	0.044

Price($)	Vol.	No.
0.050	1713619	8
0.051	1155393	5
0.052	1099239	8
0.053	1164182	8
0.054	1092392	7

Last trade - 16.10pm 16/10/2024 (20 minute delay)

IMU (ASX) Chart

Ann: Termination of Supply Agreement, page-97

Battery Age Minerals gets set to capitalise on critical mineral demand

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

James Bay latest lithium player to pivot to other metals amidst lithium slump

ASX Market Update: Index pulls back from record highs | October 16, 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Termination of Supply Agreement, page-97

Top Stories

Battery Age Minerals gets set to capitalise on critical mineral demand

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

James Bay latest lithium player to pivot to other metals amidst lithium slump

ASX Market Update: Index pulls back from record highs | October 16, 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News